Ono and DSP look to extend limaprost franchise through carpal tunnel deal
This article was originally published in Scrip
Ono will be hoping to shore up the sales of its top-selling product through an agreement with Dainippon Sumitomo Pharma to develop and market jointly in Japan limaprost alfadex for the new indication of carpal tunnel syndrome (CTS).
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.